Skip to content

JMH-011

Single arm and open-label multicenter clinical trial to evaluate the efficacy and safety of JMM-H01 in total hip arthroplasty (THA) in patients with hip joint disease

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220748
Enrollment
80
Registered
2009-06-04
Start date
2009-06-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hip joint disease caused by hip osteoarthritis and others.

Interventions

investigational material(s) Generic name etc : JMM-H01 INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : total hip arthr

Sponsors

KYOCERA Medical Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with an indication for THA who are selected by orthopedic specialist of the JOA and consented to the operation 2) Inpatients or outpatients with a written first-person consent 3) Patients aged from 40 to 75 (Not gender specific) 4) Patients with JOA score no better than 65 before THA

Exclusion criteria

Exclusion criteria: Main criteria 1) As for operative hip (1)Patients who previously had THA, osteotomy, or muscle release operation 2) As for opposite hip (1)Patients who had THA, osteotomy, or muscle release operation within a year prior to this clinical trial (2)Patients who previously had THA and the artificial joint is obviously loosened. (3)Patients who are planed to have THA, osteotomy, or muscle release operation within a year 3) Patients of multijoint disease who are diagnosed as category C by Charnley classification. 4) Patients with 80kg or more in weight, or with Body Mass Index (BMI) of 27 or more. 5) Patients who indicate or show local irritations, abscesses, pyrexia, acute bone absorption and the other symptom of infection at or around the place that the implant is used, or the ones who shows an accelerated erythrocyte sedimentation rate. 6) Patients who have pseudo- or true-metal allergy, have anaphylaxis, or have documented history of allergy or hypersensitivity to 2-methacryloyloxyethyl phosphorylcholine (MPC) and analogues.

Design outcomes

Primary

MeasureTime frame
Efficacy 1) Revision or extraction of the investigational device after THA 2) JOA score 3) X-ray photograph Safety 1) Adverse events

Secondary

MeasureTime frame
1) Improved level of JOA score 2) X-ray photograph 3) QOL assessments

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026